Contact
Please use this form to send email to PR contact of this press release:
Kalytera Therapeutics to Present New Data That Supports the Continued Investigation of KAL671 for the Treatment of Osteoporosis in Prader-Willi Syndrome at the IPWSO Conference
TO: